Skip to content

Content Library

Maximising the Chances of Immunogenicity of Neoantigen-Based Treatments to Improve Success Rates

PersImmune

Improved Induction of Neoantigen-Specific T Cell Immunity with Self-Assembling Nanoparticles

Avidea Technologies

perslmmune
avidea technologies

Neoantigen-targeting T Cell Therapy for Brain Cancer

Parker Institute for Cancer Immunotherapy (PICI)

Strategic Management of COGs and Manufacturing Turnaround for Personalized Cancer Vaccine Development

Neon Therapeutics

(PICI)
Neon Therapeutics

An Interview with Alex Franzusoff,

Chief Scientific Officer, Pact Pharma

An Interview with Jessica Baker Flentcher,

CSO, Genocea Biosciences